Investment Portfolio
The world's first company that uses artificial intelligence and 3D printing technology to provide customized treatment plans for adult spinal deformities
Exit : IPO on on Nasdaq July, 2025 ; Russell 2000® Index
Building scalable, AI-enabled blood tests that make early cancer detection more accurate, affordable, and widely accessible
- Current Stage : Pre - IPO
- Exit : Projecting IPO 2026 Q3
Upright radiotherapy solution with lower cost and fewer side effects on patients
- Current Stage : D
- Exit : Projecting IPO 2026 Q3/ Q4
FDA Cleared 3D , Real Time Endovascular Therapy Navigation Technology
- Current Stage : Pre-C
- Exit : N/A
Novel wireless, catheter-free urodynamic monitoring system
- Current Stage: B plus
- Exit : N/A
The New Frontier in Ophthalmic Care Breakthrough technologies for continuous monitoring, diagnosis, and treatment optimization
- Current Stage : Pre- B
- Exit : N/A
Personalized healthcare using patient specific imaging, providing advanced surgical planning solutions through virtual reality technology for surgeons in hospitals and private practices.
- Current Stage: B
- Exit : N/A
AI Diagnostic tool for early detection of ADRD
- Current Stage: Pre-A
- Exit : N/A
FDA Breakthrough Device, a novel vasopressor management platform clinically shown to virtually eliminate intraoperative and ICU-related hypotension
- Current Stage: A Plus
- Exit : N/A
FDA Cleared, first and only single-use cranial access kit & drill with advanced features
- Current Stage: Pre-B
- Exit : N/A
A breakthrough personalized closed-loop neuromodulation therapy for Alzheimer’s Disease that works by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory
- Current Stage: Pre-B
- Exit : N/A
FDA‑cleared eWave, a wireless 6‑lead wearable ECG system and digital cardiac monitoring platform that continuously captures heart rhythm data for clinicians and remote diagnosis
- Current Stage: Pre-B
- Exit : N/A
A New kind of neural interface using hair-thin, flexible, bioelectronic fibers that seamlessly integrate with the human body
- Current Stage: Pre-A
- Exit : N/A
Investment Portfolio
Providing revolutionizing respiratory therapy by seamlessly connecting hospital and home environments with advanced technology.
- Current Stage: Pre-B
- Exit : N/A
The First and Only Drill-Free, Patient-Specific, 3D-Printed Dental Implants Placed in Minutes
- Current Stage: A
- Exit : N/A
The First conversational AI platform to accurately and objectively analyze and track patients’ data through facial, speech and movement patterns
- Current Stage: A
- Exit : N/A
Developing high-performing low-cost molecular diagnostics
- Current Stage: A
- Exit : N/A
AI-enabled wearable devices that monitor seizures, cardiorespiratory dysfunctions, and SUDEP risk to improve safety and outcomes for people living with epilepsy.
- Current Stage: A
- Exit : N/A
The only female thyroid disease telemedicine platform in the U.S.
- Current Stage: A
- Exit : N/A
Developing automated Ultrasound with artificial intelligence
- Current Stage: A
- Exit : N/A
The world’s first HoLEP + Mapping robotic platform for benign prostatic hyperplasia surgery.
- Current Stage: A
- Exit : N/A
Innovative endovascular catheter platform designed to improve the removal of blood clots in patients suffering from acute ischemic stroke.
- Current Stage: A
- Exit : N/A
Aureka Biotechnologies: developing a best-in-class therapeutic discovery platform
- Current Stage: A
- Exit : Fund Exited
Minimally invasive interbody fusion implantation technology platform
- Current Stage: Pre-A
- Exit : N/A
The First wearable device for monitoring opioid addiction
- Current Stage: Pre-A
- Exit : N/A
The first minimally invasive robotic device used in TBM repair surgery
- Current Stage: Pre-A
- Exit : N/A
Vascular implant utilizing antithrombotic surface modification technology
- Current Stage: Pre-A
- Exit : N/A
A neurotechnology company developing a minimally invasive, endovascular platform that accesses the brain through the blood vessels to treat neurological conditions without the need for traditional skull-drilling
- Current Stage: Pre-A
- Exit : N/A
Providing accurate, affordable, and non-invasive liquid biopsy tests for early cancer detection and precision medicine.
- Current Stage: Pre-A
- Exit : N/A
First company focused on developing a minimally invasive carotid access and closure system to enable safer, more efficient stroke and carotid interventions.
- Current Stage: Seed
- Exit : N/A
A non-invasive focused-ultrasound neuromodulation platform to treat autoimmune and inflammatory diseases
- Current Stage: Seed
- Exit : N/A